From Mylan’s $5.3 billion deal for Abbott’s developed markets generic business to a trio of transactions between Novartis and GlaxoSmithKline, the number of deals granted the conditional green light in Phase 1 probes by the European Commission is gathering pace. Anne MacGregor, special counsel at Cadwalader, Wickersham & Taft, explains the reasons behind the trend and sheds light on remedies negotiations that can start even before a deal is agreed. She also offers merging companies some practical strategy advice, including not to ‘bury your head in the sand’ in case of an in-depth, Phase 2 probe.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
